EUVIMEDEUVIMED entdecken
VergleichsstudieSystematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY 4.0

Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis

Yun-Tao Mao iD, Ying Wang, Xiao-Xiao Chen, Cheng-Jiang Liu, Qi Bao

Journal of Cosmetic Dermatology · 2024

DOI: 10.1111/jocd.16105 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Yun-Tao Mao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Ipilimumab, Melanoma, Nivolumab. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have advanced the therapeutic landscape for malignant melanoma patients. However, they can cause permanent and irreversible dermatologic immune‐related adverse events (irAEs) that may lead to interruption of ICI treatment or become life‐threatening. To assess the risk of severe dermatologic irAEs (grade 3 or higher) among ICIs for advanced melanoma, we conducted a network meta‐analysis (NMA).

Methods

Phase II/III randomized controlled clinical trials (RCTs) involving ICIs were retrieved from various databases, including PubMed, Embase, Cochrane Library, and Web of Science. These trials were published from the inception of databases to October 15, 2022. In addition, the risk of severe dermatologic irAEs associated with ICI types and doses was evaluated and compared by NMA.

Results

This study included 20 Phase II/III RCTs with a total of 10 575 patients. The results indicated that ICIs carry a higher risk of severe dermatologic irAEs compared to chemotherapy. Additionally, the combinational therapy of Nivolumab + Ipilimumab was associated with a higher risk than ICI monotherapy. Comparatively, the latest treatment option involving dual ICI therapy with Relatlimab + Nivolumab showed a lower toxicity risk, but higher than Ipilimumab alone. Lastly, Nivolumab, at a dose of 3 mg/kg every 2 weeks, was observed as the lowest‐risk dosing regimen for severe dermatologic irAEs in patients with advanced melanoma.

Conclusion

The findings suggest that Nivolumab (1 mg/kg) + Ipilimumab (3 mg/kg) administered every 3 weeks should be used cautiously in patients with advanced melanoma at high risk for dermatologic irAEs. While we recommend the preferred regimen of Nivolumab (dose = 3 mg/kg, every 2 weeks).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsIpilimumabMelanomaNivolumabSkin NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicDrug EruptionsRandomized Controlled Trials as TopicSeverity of Illness Index

Stichwörter der Autor:innen

dermatologic toxicitiesimmune checkpoint inhibitorsimmunotherapymelanomameta‐analysis

Substanzen

Immune Checkpoint InhibitorsIpilimumabNivolumab

Autor:innen und Institutionen

  • Department of Nursing, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Key Laboratory of Clinical Evaluation Technology for Medical Device of Zhejiang Province, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of General Medicine, Affiliated Anqing First People's Hospital of Anhui Medical University, Anqing, China.
  • Department of Plastic and Reconstructive Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

ORCID-Profile: Yun-Tao Mao

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Mao, Y. T., Wang, Y., Chen, X. X., Liu, C. J., & Bao, Q. (2024). Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16105

Vancouver

Mao YT, Wang Y, Chen XX, Liu CJ, Bao Q. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16105

BibTeX
@article{Mao2024,
  author = {Mao, Yun-Tao and Wang, Ying and Chen, Xiao-Xiao and Liu, Cheng-Jiang and Bao, Qi},
  title = {Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis},
  journal = {Journal of Cosmetic Dermatology},
  year = {2024},
  doi = {10.1111/jocd.16105}
}
Kostenlos starten →